Escalier Biosciences, with offices in Encinitas and the Netherlands, said March 13 that it has raised $19 million in venture capital financing. Privately held Escalier is developing drugs for psoriasis and other autoimmune disorders.
The round was led by Forbion, a European life science venture fund. It included existing investors New Science Ventures and BioGeneration Ventures.
Escalier’s drug candidates are in late-stage preclinical studies. Its topical drug for psoriasis is expected to enter clinical trials in the middle of this year, the company said. The company is also developing an oral psoriasis drug.
The company’s drugs target a cell receptor found on mucus...